> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# CytomX CEO Promises First Survival Data For Colorectal Cancer Drug In January
- URL: https://www.bullished.co/cytomx-ceo-promises-first-survival-data-for-colorectal-cancer-drug-in-january-80230079/
- Published: 2026-11-06T08:12:19.000Z
- Updated: 2026-11-06T08:12:19.000Z
- Description: Varsetta-M's next update will include overall survival, which management expects to be the main goal of its first registrational study.
- Author: Matteo Parrino
- Tags: Earnings, CTMX, Industry: Healthcare

CytomX Therapeutics, a clinical-stage cancer drug developer, will give the "first look at overall survival" for its colorectal cancer drug Varsetta-M in a January update, CEO Dr. Sean McCarthy said on the company's [third-quarter earnings call](https://www.benzinga.com/news/26/11/62960154/cytomx-therapeutics-q3-2026-earnings-call-transcript?ref=bullished.co) on Thursday. He expects survival to be the primary endpoint, the main measure of success, in the first registrational study.

## January's integrated update

McCarthy said the January update will span the full phase one study, including the potential registrational strategy and the data behind it. He also said it will carry the selected dose for a later study, though he could not give any color on that dose now.

On disclosure plans, he said the company wants to show progression-free survival from the dose optimization cohorts alongside the first overall survival look from escalation and expansion. The January timing, he said, simply allows enough time for a robust update.

An analyst from JP Morgan asked what drove the shift of the monotherapy update from 2026 to January. McCarthy said that as dose optimization continued, the company wanted time for sufficient follow-up on safety and efficacy, plus feedback from regulators. Asked by a Barclays analyst whether the timing reflected conference scheduling or data maturation, he said only: "[We haven't specified](https://www.benzinga.com/news/26/11/62960154/cytomx-therapeutics-q3-2026-earnings-call-transcript?ref=bullished.co) the forum at this time."

## A registrational study in 2027

Varsetta-M is an EPCAM-targeting antibody drug conjugate that management calls first in class, the only EPCAM-directed one in clinical development. McCarthy said the first registrational study is planned for the first half of 2027, as a randomized trial with overall survival as the primary endpoint. The patient population and comparator are still being decided, with the third-line-plus setting under consideration. He estimated [35,000 addressable](https://www.benzinga.com/news/26/11/62960154/cytomx-therapeutics-q3-2026-earnings-call-transcript?ref=bullished.co) U.S. patients with third-line or later colorectal cancer.

In March, the company reported progression-free survival at doses of 8.6 and 10 milligrams per kilogram. McCarthy said grade three diarrhea was 10% in the first 20 optimization patients, against more than 30% in time-matched earlier patients. The company's goal is 20% or below.

A combination trial of Varsetta-M with bevacizumab, 5-fluorouracil and leucovorin is on track to start by year-end, he said. Initial data from the bevacizumab combination and from CX801, its masked interferon in melanoma, are due in the first half of 2027.

## Cash and quarterly results

CFO Chris Ogden said the company ended September with $348 million in cash, cash equivalents and investments, up from $330 million at June 30\. That includes $37 million from Regeneron after it selected two more targets under an expanded collaboration. Ogden projected cash runway into the second half of 2028.

Revenue was [$1.7 million](https://seekingalpha.com/news/4667446-cytomx-gaap-eps-of-0%5F09-misses-by-0%5F01-revenue-of-1%5F69m-misses-by-8%5F76m?ref=bullished.co), against $6 million a year earlier, as the Astellas collaboration ended in the second quarter of 2026\. Operating expenses rose to $25.2 million from $21.7 million.

The January update is the next date McCarthy set for overall survival, the selected dose and the registrational design.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates](https://finance.yahoo.com/healthcare/articles/cytomx-therapeutics-ctmx-reports-q3-214506853.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [CytomX GAAP EPS of -$0.09 misses by $0.01, revenue of $1.69M misses by $8.76M (CTMX:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4667446-cytomx-gaap-eps-of-0%5F09-misses-by-0%5F01-revenue-of-1%5F69m-misses-by-8%5F76m?ref=bullished.co) — seekingalpha.com
- [CytomX Therapeutics Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/11/62960154/cytomx-therapeutics-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [CytomX Therapeutics: Q3 Earnings Snapshot](https://www.seattlepi.com/business/cytomx-therapeutics-q3-earnings-snapshot-a22514998?ref=bullished.co) — seattlepi.com
- [CytomX Therapeutics Announces Q3 2026 Financial Results and](https://www.globenewswire.com/news-release/2026/11/05/3397134/0/en/cytomx-therapeutics-announces-q3-2026-financial-results-and-provides-business-update.html?ref=bullished.co) — globenewswire.com